Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.001
Buy
RSI(14)
47.670
Neutral
STOCH(KDJ)(9,3,3)
51.536
Neutral
ATR(14)
0.242
High Vlolatility
CCI(14)
-13.193
Neutral
Williams %R
53.520
Neutral
TRIX(12,20)
0.079
Sell
StochRSI(14)
0.000
Sell
Search
Pluri Inc
PLURAdd to Watchlist
3.370USD
-0.310-8.54%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
35.15MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Pluri Inc
Currency: USD Updated: 2026-05-15Key Insights
Pluri Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 156 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as , with the highest price target at 12.00.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Pluri Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Pluri Inc Highlights
StrengthsRisks
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 365.51% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.34M.
Fairly Valued
The company’s latest PE is -1.16, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.35M shares, decreasing 3.15% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 20.02K shares of this stock.
Analyst Rating
Based on
0
analysts
--
Current Rating
12.000
Target Price
+252.94%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Pluri Inc is 5.22, ranking 364 out of 382 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 167.00K, representing a year-over-year decrease of 60.89%, while its net profit experienced a year-over-year decrease of 9.74%.
Score
Financials
4.20
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.45
Operational Efficiency
2.72
Growth Potential
4.60
Shareholder Returns
7.11
Pluri Inc's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of Pluri Inc is 7.24, ranking 135 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.16, which is -47.43% below the recent high of -0.61 and -60.64% above the recent low of -1.86.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 156/382
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Pluri Inc is 8.00, ranking 161 out of 382 in the Biotechnology & Medical Research industry. The average price target is 12.00, with a high of 12.00 and a low of 12.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
No Data
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Pluri Inc is 6.60, ranking 212 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 3.87 and the support level at 2.90, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
3.468
Sell
MA10
3.414
Sell
MA20
3.411
Sell
MA50
3.352
Buy
MA100
3.353
Buy
MA200
3.811
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-15The current institutional shareholding score of Pluri Inc is 3.00, ranking 193 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 12.56%, representing a quarter-over-quarter decrease of 14.97%. The largest institutional shareholder is James Simons, holding a total of 20.02K shares, representing 0.19% of shares outstanding, with 52.71% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Pluri Inc is 2.15, ranking 238 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 0.74. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.74
VaR
+7.14%
240-Day Maximum Drawdown
+49.57%
240-Day Volatility
+95.08%
Return
Best Daily Return
60 days
+9.18%
120 days
+16.36%
5 years
+40.62%
Worst Daily Return
60 days
-6.80%
120 days
-12.71%
5 years
-17.19%
Sharpe Ratio
60 days
-0.64
120 days
+0.13
5 years
-0.20
Risk Assessment
Maximum Drawdown
240 days
+49.57%
3 years
+64.22%
5 years
+88.80%
Return-to-Drawdown Ratio
240 days
-0.50
3 years
-0.24
5 years
-0.20
Skewness
240 days
+1.20
3 years
+1.17
5 years
+0.94
Volatility
Realised Volatility
240 days
+95.08%
5 years
+100.47%
Standardised True Range
240 days
+8.59%
5 years
+17.65%
Downside Risk-Adjusted Return
120 days
+21.56%
240 days
+21.56%
Maximum Daily Upside Volatility
60 days
+51.69%
Maximum Daily Downside Volatility
60 days
+52.85%
Liquidity
Average Turnover Rate
60 days
+0.08%
120 days
+0.22%
5 years
--
Turnover Deviation
20 days
-67.22%
60 days
-69.65%
120 days
-20.28%
Peer Comparison
Biotechnology & Medical Research
Pluri Inc
PLUR
5.83 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
